We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for responding very informative.
Moniman, not an expert, but as I understand it a vaccine can be backed by a whole portfolio of patents. From the WHO website https://www.who.int/intellectualproperty/events/en/Background_paper.pdf:
`A patent shall be granted for an invention so long as it is demonstrated that the invention
passes certain necessary tests such as being “new” and involving an “inventive step” ...
Relevant patented inventions might include products
(including e.g. a micro-organism in a living but attenuated state, (recombinant) antigens and
antibodies, an adjuvant or a vaccine delivery device) and processes (e.g. relating to a method
or steps in a method for producing a vaccine).'
I'd presume any patented part of the Flu V vaccine technology (where Imutex own the patents) has the potential to be licensed out at a price beneficial to all shareholders?
I believe the tech was already under development with Peptcell before the partnership with hVivo as they were working on a HIV vaccine. Whether they put this underlying vaccine development IP into the Imutex vehicle to match hVivo's cash and study hosting I don't know. So it's hard to know if we will benefit from future developments.
Assuming we get shares in ConserV Biosciences when it floats, we will benefit from the developments. If we get cash we gain nothing from it.
All IMHO DYOR
Not being an expert on these matters but has someone ‘borrowed’ the Flu v technology for Covid vaccine and now for Malaria vaccine? Maybe it’s not the same technology but does anyone know enough to give an answer? If we have ‘lent’ the technology out, are we due any royalties?
https://www.openorphan.com/our-businesses/imutex
Not being an expert on these matters but has someone ‘borrowed’ the Flu v technology for Covid vaccine and now for Malaria vaccine? Maybe it’s not the same technology but does anyone know enough to give an answer? If we have ‘lent’ the technology out, are we due any royalties?
…………” Imutex’s proprietary peptide modelling platform could have possible uses in identifying a peptide for use in a Coronavirus vaccine by using the successful FLU-v vaccine but swapping out the universal flu peptide with a peptide specific to COVID-19. Open Orphan’s management team is optimistic about the potential to monetise these assets through licensing them to Big Pharma for further development……..”
https://clinicaltrials.gov/ct2/show/NCT03180801
https://www.openorphan.com/our-businesses/imutex
IS this another ship that has sailed?
https://www.telegraph.co.uk/global-health/science-and-disease/biontech-plans-malaria-vaccine-based-revolutionary-covid-19/?WT.mc_id=e_DM1474502&WT.tsrc=email&etype=Edi_GHS_New_Daily&utmsource=email&utm_medium=Edi_GHS_New_Daily20210804&utm_campaign=DM1474502
BioNTech plans malaria vaccine based on revolutionary Covid-19 jab technology
Scientists say mRNA technology could "open the floodgates" for developing vaccines against many other life-threatening conditions
By
Will Brown
IN NAIROBI
2 August 2021 • 9:14pm
A mosquito is held up for inspection at a research institute in Portland, Maine.
A mosquito is held up for inspection at a research institute in Portland, Maine. CREDIT: Pat Wellenbach/AP
BioNTech has announced plans to develop the world’s first mRNA-based malaria vaccine, in a potentially major step towards beating back the disease which still kills hundreds of thousands of people every year.
The German pharmaceutical company produced its enormously successful Covid-19 vaccine along with the American giant Pfizer, and says it wants to start clinical trials of a shot to prevent malaria, made using similar technology, by 2022.
Normal vaccines work by injecting a weakened or dead version of a germ into the human body to develop antibodies, but mRNA vaccines work differently. The new technology teaches cells how to make a protein that triggers an immune response, teaching the body to fight against future infections.
"The very high efficacy of two mRNA vaccines for Covid-19 have shown the world just how powerful this technology could be against many diseases, including malaria," said Tedros Adhanom Ghebreyesus chief of World Health Organization, said last week.
Earlier this year, the team behind the Oxford-AstraZeneca vaccine developed the first effective jab against the mosquito-borne disease, with a more than 75 per cent efficacy rate.
The hope is that vaccines like this could help stop the enormous and needless loss of life every year in Africa. Roughly 400,000 people die every year of the disease in sub-Saharan Africa, more than half of whom are under the age of five. Progress in tackling the ancient disease has recently stalled.
Moreover, after a year in which African nations have struggled to acquire anywhere near enough Covid-19 vaccines to immunise their populations - all of which are manufactured overseas - BioNTech said it is looking for suitable vaccine production sites on the continent.
BioNTech said the company would fund the research and initial production of the vaccine itself. Then it will turn to partners for support with large-scale trials.
Scientists have said that mRNA technology could "open the floodgates" for developing vaccines against many other life-threatening conditions.
BioNTech also plans to start a clinical trial to test a vaccine against tuberculosis in 2022. The organisation is also receiving support from the European Commission and th